Author(s)

Cassandra L. Presti^1*, Payam Katebi Kashi¹, Christopher M. Tarney², Ruchi Garg^1,3

¹Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Inova Fairfax Women’s Hospital, Falls Church, VA, USA.
²Walter Reed National Military Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Bethesda, MD, USA.
³Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates, Fairfax, Virginia, USA.

Background: Neoadjuvant chemotherapy is used in gynecologic malignancies as primary treatment for advanced disease and has demonstrated improvement in survival rates. However, the data for use in endometrial cancer is limited. Case: This is a case of stage IV endometrial undifferentiated carcinoma with complete response to four cycles of neoadjuvant chemotherapy (carboplatin/paclitaxel) and no evidence of disease during the interval debulking surgery (robotic-assisted total laparoscopic hysterectomy with bilateral salpingoophorectomy, pelvic and paraaortic lymph node dissection, and cystoscopy). Conclusion: Complete response to neoadjuvant chemotherapy prior to interval debulking surgery is only reported in a limited number of cases, and even less common in advanced stage high-grade endometrial cancers. The use of neoadjuvant chemotherapy may reduce tumor burden, increase opportunities for optimal debulking, and have an impact on survival. Further research is needed to understand the potential for neoadjuvant chemotherapy in these patients.

Neoadjuvant Chemotherapy, Undifferentiated Endometrial Carcinoma

Presti, C. , Kashi, P. , Tarney, C. and Garg, R. (2020) Advanced Undifferentiated Endometrial Carcinoma with No Evidence of Disease after Neoadjuvant Chemotherapy: A Case Report. Open Journal of Obstetrics and Gynecology, 10, 1573-1579. doi: 10.4236/ojog.2020.10110141.